Welcome to our dedicated page for Celldex Therapeutics SEC filings (Ticker: CLDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celldex Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing antibody-based therapeutics in immunology and mast cell-mediated disease. Its 8-K reports furnish financial results and corporate updates, including clinical and regulatory disclosures for barzolvolimab programs and other pipeline candidates, as well as material-event and capital-structure disclosures related to common stock financing.
Proxy materials describe annual stockholder voting matters, director elections, auditor ratification, executive compensation and equity incentive plan proposals. The filing record also identifies Celldex common stock, par value $.001, trading under CLDX on the Nasdaq Capital Market.
Celldex Therapeutics, Inc. reported that SVP of Corporate Affairs & Administration Sarah Cavanaugh received a grant of incentive stock options. She was awarded options covering 95,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.
Following this grant, she holds derivative securities for 95,000 underlying shares. The options have a long-term vesting schedule: 25% vest on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the subsequent 12 quarters, and they expire on June 25, 2036.
Celldex Therapeutics, Inc. reported that senior vice president and chief product development officer Elizabeth Crowley received a grant of options covering 100,000 shares of common stock. These incentive stock options have an exercise price of $34.09 per share and expire on June 25, 2036.
According to the disclosure, 25% of the options vest on June 25, 2027, with the remaining options vesting in equal quarterly installments over the following 12 quarters. After this grant, Crowley holds derivative securities representing 100,000 options directly.
Celldex Therapeutics, Inc. granted Senior Vice President and Chief Business Officer Ronald Pepin an incentive stock option covering 20,000 shares of common stock. The option has an exercise price of $34.09 per share and was issued under the company’s 2021 Omnibus Equity Incentive Plan.
According to the vesting schedule, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The option expires on June 25, 2036, and Pepin holds 20,000 derivative securities following this grant.
Celldex Therapeutics, Inc. Executive VP & Chief Scientific Officer Tibor Keler received an incentive stock option grant covering 115,000 shares of common stock. The option has an exercise price of $34.09 per share and expires on June 25, 2036.
According to the vesting terms, 25% of the option vests on June 25, 2027, with the remaining 75% vesting in equal quarterly installments over the following 12 quarters. After this grant, Keler holds options for 115,000 underlying shares directly.
Celldex Therapeutics, Inc. reported that President and CEO Anthony S. Marucci received a grant of 375,000 Incentive Stock Options to buy Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan.
These options start vesting with 25% becoming exercisable on June 25, 2027, and the remaining 75% vesting in equal quarterly installments over the following 12 quarters. The options expire on June 25, 2036. This is a compensation-related award, not an open-market purchase or sale.
Celldex Therapeutics, Inc. reported that director Denice Torres received a grant of 26,000 non-qualified stock options to buy Celldex common stock. The options have an exercise price of $34.09 per share, were granted as of June 25, 2026, and expire on June 25, 2036. Following this award, Torres holds 26,000 derivative securities directly.
Jain Rita reported acquisition or exercise transactions in this Form 4 filing.
Celldex Therapeutics director Rita Jain received a grant of 26,000 non-qualified stock options to buy common stock at $34.09 per share.
The options were granted at no cost under the company’s 2021 Omnibus Equity Incentive Plan, are first exercisable on June 25, 2027, and expire on June 25, 2036.
Celldex Therapeutics director Neil Garry Arthur received a compensation-related stock option grant. He was awarded non-qualified options to acquire 26,000 shares of Celldex common stock at an exercise price of $34.09 per share under the company’s 2021 Omnibus Equity Incentive Plan. These options become exercisable starting on June 25, 2027 and expire on June 25, 2036, and this grant represents the full 26,000 derivative shares reported as held following the transaction.
Celldex Therapeutics director Cheryl Cohen received a grant of 26,000 stock options. The non-qualified options give her the right to buy 26,000 shares of Celldex common stock at an exercise price of $34.09 per share. They were awarded under the company’s 2021 Omnibus Equity Incentive Plan.
After this grant, she holds 26,000 derivative securities directly, with the options exercisable starting June 25, 2027 and expiring on June 25, 2036. The filing reports no share sales or open-market purchases, indicating a routine equity compensation award rather than a market trade.
Celldex Therapeutics director Keith L. Brownlie received a grant of 26,000 stock options as part of his compensation. These non-qualified options allow him to buy Celldex common stock at an exercise price of $34.09 per share, under the company’s 2021 Omnibus Equity Incentive Plan.
The options become exercisable starting on June 25, 2027 and expire on June 25, 2036. Following this award, Brownlie is reported as holding 26,000 derivative securities (options) of this type.